GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Forward Rate of Return (Yacktman) %

TOI (The Oncology Institute) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. The Oncology Institute's forward rate of return for was 0.00%.

The historical rank and industry rank for The Oncology Institute's Forward Rate of Return (Yacktman) % or its related term are showing as below:

TOI's Forward Rate of Return (Yacktman) % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 15.74
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


The Oncology Institute Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for The Oncology Institute's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute Forward Rate of Return (Yacktman) % Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial - - - - -

The Oncology Institute Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of The Oncology Institute's Forward Rate of Return (Yacktman) %

For the Medical Care Facilities subindustry, The Oncology Institute's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute's Forward Rate of Return (Yacktman) % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Forward Rate of Return (Yacktman) % falls into.



The Oncology Institute Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

The Oncology Institute's Forward Rate of Return of Sep. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.3269+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Oncology Institute  (NAS:TOI) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


The Oncology Institute Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


The Oncology Institute Business Description

Traded in Other Exchanges
N/A
Address
18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Executives
Brad Hively director, officer: Chief Executive Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Havencrest Healthcare Partners, L.p. 10 percent owner 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah officer: Chief Financial Officer, other: Principal Financial Officer C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Jeremy Castle officer: Chief Operating Officer 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch director, officer: Executive Chairman C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos officer: Chief Medical Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit officer: Chief Accounting Officer, other: Principal Accounting Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal director 44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian 10 percent owner C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara director C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201